CoChat

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.

Abstract

Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrc2615

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 185

Metadata

Authors
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L.
Affiliations
  • Walter and Eliza Hall Institute of Medical Research (AU)
  • The Royal Melbourne Hospital (AU)
Corresponding author
  • Cragg, Mark S.
  • Scott, Clare L.
Venue
Nature Reviews Cancer
Published
2009-04-03
Volume
9
Issue
5
Pages
321-326
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W2065336454
Cited by
185
References
58
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 12 · 2021: 8 · 2020: 6 · 2019: 4 · 2018: 8 · 2017: 8 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 16 · 2012: 15
FWCI
1.53
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature reviews. Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
Funders
National Cancer Institute
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
BH3 mimetics, ABT-737, apoptosis, targeted cancer therapy, combination therapy
MeSH terms
Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biphenyl Compounds, Humans, Nitrophenols, Piperazines, Sulfonamides, Fusion Proteins, bcr-abl, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.